Clincosm LogoSign in Get a demo

TAPS01: Therapeutics in Active Prostate Cancer Surveillance

Sponsor
CCTU- Cancer Theme (Other)
Overall Status
Completed
CT.gov ID
NCT03365297
Collaborator
Janssen-Cilag Ltd. (Industry)
11
Enrollment
1
Location
1
Arm
13.6
Actual Duration (Months)
0.8
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Testing if short-term use of apalutamide can reduce image defined tumour volumes in men with detectable lesion on multi-parametric Magnetic Resonance Imaging (mpMRI) and being managed by Active Surveillance. The trial will also evaluate the tolerability and side effect profile of men on AS using short term apalutamide and patient acceptability as a therapeutic strategy, as well as determining feasibility of a larger prospective randomised trial of apalutamide.

Condition or Disease Intervention/Treatment Phase
Phase 2

Detailed Description

The numbers of men diagnosed with prostate cancer in the United Kingdom (UK) and worldwide is increasing. In the UK 46,690 men were diagnosed in 2014 alone and it is estimated this figure will be closer to 70,000 by 2030. A significant proportion of these men will present with organ confined and low or intermediate risk disease. There is increasing recognition that many men with low and intermediate risk prostate cancer do not need immediate radical therapy.

There is sufficient evidence that pharmacological intervention used as short-term therapy in men with low to intermediate-risk disease can inhibit the growth of prostate tumours and delay or remove the need for radical therapy in men managed by active surveillance. Given the irrefutable role of the androgen receptor in prostate cancer pathogenesis it is logical to target this pathway as a method of inhibiting or delaying disease progression.

This window study will be built on the known anti-androgen effects of apalutamide and investigate the efficacy of using it as a short intervention strategy to cause a physiological change in the tumour by reducing its volume. Tumour volume can be measured using the well-established place of mpMRI defined tumour volumes as a surrogate of disease presence and change. The rationale for a short duration treatment is that it will not have the long term debilitating effects of androgen deprivation on general health and prevent the onset of androgen resistance.

It is anticipated that if successful, this approach could be a new therapeutic strategy for these men who otherwise are living and waiting for their disease to progress or not.

Study Design

Study Type:
Interventional
Actual Enrollment :
11 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Intervention Model Description:
Single centre, single arm open labelled Phase II window studySingle centre, single arm open labelled Phase II window study
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Targeted Drug Intervention to Inhibit Cancer Progression in Men on Active Surveillance for Prostate Cancer. Therapeutics in Active Prostate Cancer Surveillance (TAPS01)
Actual Study Start Date :
Jun 5, 2018
Actual Primary Completion Date :
Jul 25, 2019
Actual Study Completion Date :
Jul 25, 2019

Arms and Interventions

Arm Intervention/Treatment
Experimental: Treatment

apalutamide, 240mg (4x60mg tablets) orally, daily for a max. duration of 90 continuous days.

Drug: Apalutamide
240mg (4x60mg) oral tablets daily over a max. of 90 days
Other Names:
  • ARN509
  • JNJ-56021927

    		•

    Outcome Measures

    Primary Outcome Measures

    1. Physiological Response [over a 90 day treatment period]

      Tumour volume downsizing/absence of lesion, as determined by mpMRI

    Secondary Outcome Measures

    1. Patient Reported Outcomes [over 120 days]

      Function and wellbeing using established standardised EQ-5D-5L and EORTC-QLQ30+PR25 module questionnaires

    2. Adverse Events [over 120 days]

      tolerability and side effect profile

    Other Outcome Measures

    1. Patient acceptability [over an estimated 1 year recruitment period]

      number of men approached versus recruited

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    Male
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:

    • Given Informed Consent (IC) to participate

    • Age 18 or over

    • Eastern Cooperative Oncology Group (ECOG) status 0-2

    • Diagnosed with prostate cancer

    • Patient selection of active surveillance as a management option

    • mpMRI detectable lesion

    • Prostate cancer on biopsy from a mpMRI defined lesion

    • No contraindications to apalutamide

    • Normal full blood count and normal renal and liver function tests

    • At least 6 months since initiation of active surveillance and/or last rebiopsy date.

    • Low or intermediate risk prostate cancer according to National Institute for Health and Care Excellence (NICE) classification

    • M score of ≥ 3 using Prostate Imaging Reporting and Data System (PIRADS) version 2 reporting criteria

    Exclusion Criteria:

    • Contraindications to apalutamide or its excipients

    • Concurrent medication that can lower seizure threshold

    • Prior localised therapy for prostate cancer

    • Any prior use of androgen deprivation therapy or androgen receptor targeting agents

    • Any prior systemic therapy for prostate cancer

    • Patient unable to have prostate 3T mpMRI scan

    • Presence of any pelvic or hip metalwork

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Cambridge University Hospitals NHS Foundation Trust/Addenbrookes Hospital Cambridge Cambridgeshire United Kingdom CB2 0QQ

    Sponsors and Collaborators

    • CCTU- Cancer Theme
    • Janssen-Cilag Ltd.

    Investigators

    • Principal Investigator: Vincent J Gnanapragasam, Cambridge University Hospitals NHS Foundation Trust/University of Cambridge

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    CCTU- Cancer Theme, CCTU Cancer Theme, Cambridge University Hospitals NHS Foundation Trust
    ClinicalTrials.gov Identifier:
    NCT03365297
    Other Study ID Numbers:
    • TAPS01
    • 2017-001700-29
    First Posted:
    Dec 7, 2017
    Last Update Posted:
    Nov 19, 2019
    Last Verified:
    Jun 1, 2018
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:
    Prostatic Neoplasms

    Study Results

    No Results Posted as of Nov 19, 2019